Blood test could replace tissue biopsy for prostate cancer gene screening

NCT ID NCT06762379

Recruiting now Knowledge-focused Sponsor: European Institute of Oncology Source: ClinicalTrials.gov ↗

Summary

This study aims to develop and test a new blood-based method for detecting specific gene mutations in men with metastatic prostate cancer. Researchers will enroll 125 patients whose tumor tissue samples are unavailable or inadequate for standard testing. The goal is to create a better testing algorithm that could help guide treatment decisions without requiring invasive tissue biopsies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER (MPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

European Institute of oncology
RECRUITING

Milan, Italy, 20141, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC PROSTATE CANCER (MPC)